Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review

Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Repligen and Compass Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$634.44 million	13.92	$35.60 million	($0.51)	-309.16
Compass Therapeutics	$850,000.00	448.38	-$42.49 million	($0.37)	-7.49

Repligen has higher revenue and earnings than Compass Therapeutics. Repligen is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

97.6% of Repligen shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 1.2% of Repligen shares are held by company insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Repligen and Compass Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repligen	-4.64%	4.21%	2.94%
Compass Therapeutics	N/A	-32.37%	-30.67%

Risk & Volatility

Repligen has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Repligen and Compass Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0	5	8	0	2.62
Compass Therapeutics	0	2	7	0	2.78

Repligen presently has a consensus target price of $181.00, indicating a potential upside of 14.80%. Compass Therapeutics has a consensus target price of $11.38, indicating a potential upside of 310.65%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Repligen.

Summary

Compass Therapeutics beats Repligen on 8 of the 14 factors compared between the two stocks.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.